BRIEF-Arrivent Announces First Patient Dosed In Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib For First-Line Treatment Of EGFR PACC Mutant Non-Small Cell Lung Cancer
Reuters
Dec 22, 2025
BRIEF-Arrivent Announces First Patient Dosed In Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib For First-Line Treatment Of EGFR PACC Mutant Non-Small Cell Lung Cancer
Dec 22 (Reuters) - Arrivent Biopharma Inc AVBP.O:
ARRIVENT ANNOUNCES FIRST PATIENT DOSED IN GLOBAL PIVOTAL PHASE 3 ALPACCA TRIAL EVALUATING FIRMONERTINIB FOR FIRST-LINE TREATMENT OF EGFR PACC MUTANT NON-SMALL CELL LUNG CANCER
Source text: ID:nGNXJ44p
Further company coverage: AVBP.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.